Received Apr 9, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
Flu like symptoms for 3 days; This non-serious case was reported by a physician via sales rep and described the occurrence of influenza-like symptoms in a 17-year-old male patient who received Men B NVS (Bexsero) for prophylaxis. On 25-MAR-2026, the patient received the 1st dose of Bexsero. On 26-MAR-2026, 1 days after receiving Bexsero, the patient experienced influenza-like symptoms (Verbatim: Flu like symptoms for 3 days). On 28-MAR-2026, the outcome of the influenza-like symptoms was resolved (duration 2 days). It was unknown if the reporter considered the influenza-like symptoms to be related to Bexsero. The reporter considered the influenza-like symptoms to be related to Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the influenza-like symptoms to be related to Bexsero. The company considered the influenza-like symptoms to be related to Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-APR-2026 The batch number was not provided upon follow up with the reporter.